Clinical Trials Directory

Trials / Terminated

TerminatedNCT00232271

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Melbourne Health · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane on the development of leg clots following electrophysiology studies (EPS) and or radiofrequency ablation (RFA). People who suffer heart palpitations will sometimes need hospital admission to undergo an electrophysiology study ( and or a Radiofrequency Ablation)in order to diagnose and or treat their condition. Radiofrequency ablation is a procedure to stop abnormal heart rhythms. EPS/RFA studies require the puncture of the leg veins . Previous experience has shown that following the puncture of leg veins there is a small risk of developing a blood clot in the leg. It is not known whether giving blood thinners (anticoagulants) after the procedure will decrease this risk Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs

Conditions

Interventions

TypeNameDescription
DRUGClexane

Timeline

Start date
2005-08-01
Primary completion
2011-01-01
Completion
2011-02-01
First posted
2005-10-04
Last updated
2013-05-30

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT00232271. Inclusion in this directory is not an endorsement.